Omeros
Logotype for Omeros Corp

Omeros (OMER) investor relations material

Omeros Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Omeros Corp
Q3 2026 earnings summary16 Nov, 2026

Executive summary

  • YARTEMLEA Q3 gross revenue was $41.8 million, up 29.6% QoQ; net sales were $35.9 million, up 26%.

  • Operating cash flow was positive for a second consecutive quarter at $13.3 million; cash and short-term investments totaled $95.3 million.

  • Operating income was $4.5 million, while GAAP net loss was $57.4 million, primarily due to a $62.0 million non-cash derivative remeasurement loss.

Financial highlights

  • Adjusted net income, excluding non-cash fair-value remeasurement, was $4.7 million, or $0.06 per share, versus $1.8 million, or $0.02 per share, in Q2.

  • Q3 net product sales were $35.9 million; 9M sales were $74.4 million. Gross-to-net adjustments were 14.0% in Q3 and 12.7% for 9M.

  • Q3 R&D was $16.1 million and SG&A was $14.5 million; 9M operating loss narrowed to $12.8 million from $93.7 million.

  • 9M operating cash flow was $2.9 million, versus cash used of $76.3 million in 9M 2025.

  • Q3 GAAP loss per share was $0.79; 9M net income was $11.9 million versus a $89.8 million loss in 9M 2025.

Outlook and guidance

  • Q4 R&D is expected to exceed Q3, led by YARTEMLEA, other MASP-2 programs, and ONCOTOX-AML; SG&A is expected to be slightly higher with commercial expansion.

  • Q4 interest expense is expected to be comparable to Q3; income from discontinued operations is expected at $5 million-$6 million, excluding non-cash OMIDRIA royalty-asset remeasurement.

  • YARTEMLEA revenue momentum continued into Q4; 2027 guidance will follow when there is greater sales visibility. Cash and expected sales are expected to fund more than 12 months of operations.

  • OMS527 patient-trial enrollment is expected in Q1 2027 after an additional FDA-requested nonclinical study; OMS805 Phase 1b is targeted for late 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Omeros earnings date

Logotype for Omeros Corp
Q4 20261 Apr, 2027
Omeros
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Omeros earnings date

Logotype for Omeros Corp
Q4 20261 Apr, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Omeros Corp is a biopharmaceutical company focused on developing and commercializing small-molecule and protein therapeutics. The company's research is centered on treatments for inflammation, immune disorders, and central nervous system conditions. Omeros also explores therapies targeting complement-mediated diseases, aiming to address various unmet medical needs. Its pipeline includes both clinical-stage and preclinical programs, with a focus on advancing innovative therapies that modulate key biological pathways involved in immune and inflammatory responses. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.